Ivenix acquired by Fresenius
Context
Fresenius Kabi agreed to acquire 100% of Ivenix, delivering on its "Expand MedTech" growth vector under its Vision 2026 strategy. The combination of Ivenix's leading hardware and software infusion platform with Fresenius Kabi's existing intravenous fluids and infusion device portfolio creates a comprehensive premium MedTech offering for the US market. Significant scale and growth synergies are expected from the transaction. The Ivenix Infusion System is expected to be neutral to Fresenius Kabi's Group cash earnings per share in 2025 and accretive from 2026 onwards.
By taking control of Ivenix, Fresenius continues its expansion strategy. Previously, the group had completed 2 acquisitions, including Eugin Group in 2020.
Ivenix, which reported an EBITDA margin of [members only] in 2022, is valued in this transaction at an EV/EBITDA multiple of [members only], to compare with the average observed in the Healthcare & Pharma sector (16.1x in 2022).
-> Deep-dive in Healthcare & Pharma market trends
Target
Ivenix is a privately held US-based medical technology company specialising in next-generation infusion therapy systems. The company has developed what is considered the technologically most advanced infusion system available, comprising a large volume pump (LVP) with administration sets, infusion management software tools, applications, and analytics designed to improve care delivery and operational efficiency. The Ivenix Infusion System sets a new standard in infusion safety, simplicity, and interoperability, centred around the patient and clinician experience, and is specifically designed to reduce infusion-related errors and lower the total cost of ownership for healthcare providers. The system received FDA approval and was successfully commercially launched in the United States in late 2021.
Ent. Value
[members only]
Equity Value
[members only]
Multiples
EV / Revenue
[members only]
EV / EBITDA
[members only]
EV / EBIT
[members only]
Historical Financials (USD)
Other operations with Fresenius
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 03/2022 | FRESENIUS | MABXIENCE | SPAIN | CDMO |
| 12/2020 | FRESENIUS | EUGIN GROUP | SPAIN | Outpatient Care |
| 09/2017 | FRESENIUS | NXSTAGE MEDICAL | UNITED STATES | Diagnostic Equipment |
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 05/2022 | ASTORG | CORDENPHARMA | SWITZERLAND | CDMO |
| 04/2022 | HALDER | CPM GROUP | GERMANY | Implants & Prosthetics |
| 03/2022 | FRESENIUS | MABXIENCE | SPAIN | CDMO |
| 02/2022 | MONTAGU PRIVATE EQUITY / PARTNERS GROUP | HTL BIOTECHNOLOGY | FRANCE | CDMO |
| 01/2022 | ARDIAN | BIOFARMA GROUP | ITALY | CDMO |
| 01/2022 | PERMIRA | BIO PRODUCTS LABORATORY (BPL) | UNITED KINGDOM | CDMO |
| 01/2022 | PERMIRA | KEDRION | ITALY | CDMO |
| 01/2022 | ANJAC BEAUTY & HEALTH | APOLLO HEALTHCARE CORP.. | CANADA | CDMO |
| 12/2021 | PLANMECA GROUP | KAVO DENTAL | GERMANY | Medical Devices |
| 12/2021 | WINNCARE | PHARMAOUEST INDUSTRIES | FRANCE | Medical Devices |
REFERENCES
Revenue range: REV 1m USD - 100m USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Ivenix by Fresenius are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Acquirer: fresenius
FAQ
What transaction does this page cover?
How does the valuation of Ivenix compare to benchmarks in the Healthcare & Pharma sector?
What sources support the information on this transaction?
What is mynth?